HC Wainwright Boosts Earnings Estimates for Co-Diagnostics

Co-Diagnostics, Inc. (NASDAQ:CODX) – Investment analysts at HC Wainwright raised their FY2025 earnings per share estimates for shares of Co-Diagnostics in a research note issued to investors on Monday, November 24th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.72) per share for the year, up from their previous forecast of ($0.79). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Co-Diagnostics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Co-Diagnostics’ Q4 2025 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.36) EPS.

Co-Diagnostics (NASDAQ:CODX) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. Co-Diagnostics had a negative net margin of 6,347.34% and a negative return on equity of 70.26%. The firm had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.30 million.

Other research analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Co-Diagnostics in a research report on Thursday, October 30th. Maxim Group raised Co-Diagnostics to a “hold” rating in a report on Wednesday. D. Boral Capital restated a “buy” rating and issued a $3.00 price objective on shares of Co-Diagnostics in a research report on Tuesday, October 28th. Finally, Wall Street Zen upgraded Co-Diagnostics to a “hold” rating in a research report on Saturday, November 1st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Co-Diagnostics has a consensus rating of “Hold” and a consensus target price of $1.83.

Co-Diagnostics Price Performance

Shares of NASDAQ CODX opened at $0.37 on Wednesday. Co-Diagnostics has a 12-month low of $0.23 and a 12-month high of $1.55. The company has a market capitalization of $22.73 million, a PE ratio of -0.38 and a beta of 0.98. The firm’s 50-day moving average is $0.40 and its two-hundred day moving average is $0.33.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Co-Diagnostics stock. Jane Street Group LLC boosted its stake in Co-Diagnostics, Inc. (NASDAQ:CODX) by 314.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 166,254 shares of the company’s stock after purchasing an additional 126,105 shares during the quarter. Jane Street Group LLC owned about 0.50% of Co-Diagnostics worth $47,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 14.99% of the company’s stock.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.